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Abstract Maspin is a serine protease inhibitor whose
gene is located on 3q27. Several lines of evidence point
towards its putative role as tumor suppressor gene and
angiogenesis inhibitor; however, there are compelling
data showing that maspin is also expressed in the nuclear
compartment and might be associated with the differenti-
ation of specific cell lineages. No systematic study of
maspin expression in normal skin and usual skin carcino-
mas have been published so far. We semiquantitatively
analyzed the distribution and immunoreactivity pattern
of maspin in 14 squamous cell carcinomas (SCCs) and
16 basal cell carcinomas (BCCs) and in the adjacent nor-
mal epidermis of all cases. We also examined the corre-
lation of maspin expression with histological type, grade,
vascular invasion, perineural infiltration, and mitotic
counting. Cytoplasmic expression of maspin was ob-
served in suprabasal, prickle, and granular cell layers of
normal epidermis; cells of the germinative hair matrix,
Henle’s and Huxley’s layers, and cuticle of hair follicles;
mature sebaceous cells and sweat gland’s secretory cells.
Nuclear expression was detected in some basal/myoepi-
thelial cells of the sweat glands and scattered mature se-
baceous cells. All SCCs but one grade IV SCC showed
maspin expression, and it was correlated with the differ-
entiation of these neoplasms. BCCs presented variable
maspin expression, while metatypical carcinomas
showed moderate to intense maspin expression, nodular
BCCs variable contents of maspin and displayed a pecu-
liar distribution, confined to the center of the neoplastic
nodules. Two BCCs and one SCC showed maspin nucle-
ar expression. No correlation with other clinical patho-
logical features was observed. Our findings do not sup-
port the role of maspin as a tumor suppressor gene and
suggest that this serpin is probably associated with spe-
cific lines of differentiation.
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Introduction
Mammary serpin, also known as maspin, is a serine pro-
tease inhibitor that was originally isolated by subtractive
hybridization and differential display techniques compar-
ing mammary epithelial cells and mammary carcinomas
[9, 14, 37]. Its gene is located on 18q21 and encodes a
serine protease inhibitor of 42 kDa that putatively has tu-
mor suppressor [9, 14, 15, 22, 27, 28, 37] and antiangio-
genic activity [9, 14, 36, 37]. Moreover it has been pro-
posed that maspin blocks plasminogen activator [27, 28],
a factor that mediates cellular invasion and migration.
Despite the huge amount of data concerning the expres-
sion of maspin and its correlations with biological proper-
ties of human breast [9, 14, 15, 22, 27, 28, 36, 37], pros-
tate [18, 27, 31, 35], and pancreatic carcinomas [16, 17]
and cell lines [9, 14, 15, 16, 17, 18, 22, 27, 28, 31, 35, 36,
37], little is know on maspin expression in other tissues.
Recently our group [23, 25] and others [12, 17, 20]
demonstrated that maspin is consistently expressed in
normal and hyperplastic myoepithelial cells and in myo-
epithelial cell tumors. Moreover, we also observed that
peculiarly aggressive types of breast neoplasms do ex-
press maspin [24] despite their very aggressive behavior.
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In addition, it has been reported that maspin is also ex-
pressed in the nuclei of myoepithelial [23, 25], pancreat-
ic [17], and breast secretory cells [20]. These findings
prompted us to evaluate the hypothesis that maspin ex-
pression is also associated with specific differentiations
in some cell types.
Myoepithelial cells and terminally differentiated squa-
mous cells show some similarities regarding differentia-
tion markers, such as keratins 5 and 14. In addition, Katz
and Taichman [11], using two-dimensional gel electro-
phoresis, have reported that maspin is one of the serpins
secreted by human keratinocytes. We therefore hypothe-
sized that maspin is expressed in keratinocytes and in epi-
dermal tumors. Interestingly, no systematic evaluation of
maspin expression in normal cutaneous tissues or usual
skin carcinomas has yet been performed. We describe
here the expression of maspin in normal epidermis, cuta-
neous appendages, in situ squamous cell carcinoma
(SCC), invasive SCC, and basal cell carcinoma (BCC).
Material and methods
Cases selection
Fourteen consecutive cases of SCC, with and without an associate
in situ component, and 17 consecutive cases of BCC were retro-
spectively retrieved from the files of the Department of Pathology,
Hospital Fernando da Fonseca, Lisbon, Portugal. Patients’ ages
ranged from 32 to 82 years (median: SCCs 62, BCCs 73.5). All
patients were white and all tumors affected sun-exposed skin. Ta-
ble 1 summarizes the clinical pathological data. The clinical and
pathological data were collected from the pathology reports. All
cases were independently reviewed by three of the authors
(J.S.R.F., B.T., F.C.S.) and the diagnoses were reconfirmed in all
but one case (one “metatypical” carcinoma was reclassified as
SCC). SCCs were graded according to Broders’ criteria [13, 19]
and BCCs were classified according to Rippey’s classification
[26]. All cases were also classified according to the presence of in
situ component, growth pattern (infiltrative vs. expansive), degree
of desmoplasia, presence of vascular/lymphatic invasion, and peri-
neurial infiltration. Mitotic counting was performed by two of the
authors (J.S.R.F., B.T.) and is reported as the number of mitotic
figures per ten consecutive high power magnification fields (HPF)
in the most proliferative areas.
Immunohistochemical analysis
For all cases a 4-µm histological section was cut and mounted on a
silane-coated slide. Immunohistochemistry using the streptavidin-
biotin-peroxidase technique with a monoclonal antibody raised
against maspin (Novocastra, clone EAW24, 1:50, Newcastle, UK)
was performed as described elsewhere [23]. Heat-induced antigen
retrieval using Dako Antigen Retrieval Solution (Dako, Glostrup,
Denmark) was previously performed in a wet bath during 20 min
in all cases. Positive and negative controls were included in each
slide run. Nuclear, cytoplasmic, and membranous staining were
accepted as specific.
The distribution of maspin expression was evaluated in normal
epidermis, sweat glands, sebaceous glands, hair follicles, dermal
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Table 1 Summary of pathological clinical data of the cases (BCC basal cell carcinoma, ND not done, SCC squamous cell carcinoma)
Biopsy Age Diagnosis Histological Borders Desmoplasia Perineurial Vascular Mitotic 
no. (years) type/grade invasion invasion counting
1 77 BCC Metatypical Infiltrative Intense Present Absent 24
2 66 BCC Metatypical Infiltrative Intense Absent Absent 34
3 75 BCC Metatypical Infiltrative Intense Absent Present 56
4 82 BCC Nodular Expansive Low Absent Absent 18
5 80 BCC Mixed Infiltrative Low Absent Absent 29
6 59 BCC Mixed Infiltrative Moderate Absent Absent 23
7 62 BCC Mixed Infiltrative Moderate Absent Present 31
8 72 BCC Nodular Expansive Low Absent Absent 42
9 70 BCC Nodular Expansive Moderate Absent Absent 10
10 75 BCC Nodular Expansive Low Absent Absent 19
11 80 BCC Micronodular Expansive Low Absent Absent 4
12 63 BCC Nodular Expansive Low Absent Absent 2
13 75 BCC Nodular Expansive Low Absent Absent 46
14 64 BCC Nodular Expansive Low Absent Absent 16
15 64 BCC Nodular Expansive Low Absent Absent 8
16 75 BCC Nodular Expansive Low Absent Absent NDa
17 76 SCC Grade I Expansive Moderate Absent Absent 11
18 75 SCC Grade I Expansive Moderate Absent Absent 26
19 67 SCC Grade I Infiltrative Moderate Absent Absent 30
20 54 SCC Grade I Infiltrative Intense Absent Absent 45
21 57 SCC Grade II Infiltrative Moderate Absent Present 54
22 66 SCC Grade II Infiltrative Moderate Present Present 13
23 42 SCC Grade II Infiltrative Moderate Present Absent 26
24 32 SCC Grade II Infiltrative Intense Absent Absent 33
25 74 SCC Grade II Infiltrative Moderate Absent Absent 13
26 55 SCC Grade III Expansive Moderate Absent Absent 33
27 71 SCC Grade III Infiltrative Moderate Absent Absent 19
28 59 SCC Grade III Infiltrative Moderate Absent Present 181
29 62 SCC Grade III Infiltrative Moderate Absent Present 74
30 67 SCC Grade IV, spindle Infiltrative Moderate Present Present 16
cell carcinoma
a Insufficient tumor area to proceed mitotic counting
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mesenchymal cells, endothelial cells, pericytes, erector muscles,
nerve bundles, and adipocytes. Semiquantitative assessment of ma-
spin expression was performed for in situ SCCs, invasive SCCs, and
BCCs, according to the following criteria: - negative nuclear stain-
ing of neoplastic cells; +, focal (<5%) positivity of neoplastic cells;
++, moderate (5–50%) positivity of neoplastic cells; +++, diffuse
(>50%) positivity of neoplastic cells. Owing to the remarkable dif-
ferential expression of maspin in cells showing basal cell-like/undif-
ferentiated morphology and terminally differentiation morphology
in SCC and BCC, maspin expression was semiquantified separately
in each cell type. Moreover, we also evaluated the overall nuclear
and cytoplasmic maspin expression in both cell types.
Statistical analysis
Statistical analysis was evaluated using Statview software. Statis-
tical differences between maspin expression and histological type,
histological grade of SCCs, BCC types, presence of vascular/lym-
phatic invasion, presence of perineurial infiltration were calculat-
ed using χ2 test. Analysis of variance with Yates’ correction was
used to compare the extension and pattern of maspin expression
mean values for mitotic counting. Differences at the level of
P<0.05 were considered statistically significant.
Results
Clinical and pathological data
All SCCs showed variable keratinization; according to
Broders’ criteria [13, 19], four were classified as grade I,
five as grade II, four as grade III, and one as grade IV.
The grade IV was a bona fide example of spindle cell
SCC, showing intersecting fascicles of variably pleomor-
phic spindle cells. In seven cases an associated in situ
component was depicted [13, 19]. Eleven cases showed
infiltrative borders and three a remarkably expansive
growth pattern. Twelve cases showed moderate desmo-
plasia and two intense desmoplastic stroma. Vascu-
lar/lymphatic invasion was observed in five cases, and
perineurial invasion in only three cases. Mitotic figures
ranged from 11 to 181 per 10 HPF, with a mean of 41 in
SCCs and 28 in BCCs.
Fig. 1A–D Maspin expression in normal skin. A Normal epider-
mis showing maspin expression in suprabasal, and granulous
prickle layers. B Hair follicle, anagen growth phase: maspin ex-
pression in mature hair matrix cells and cells of the Henley’s and
Huxley’s layers and in the hair cuticle. C Sebaceous glands deco-
rated by maspin. D Sweat glands showing maspin nuclear expres-
sion in basal cells and some secretory cells with cytoplasmic and
nuclear expression. Inset Note nuclear expression in basal cells of
an eccrine sweat gland. Streptavidin-biotin-peroxidase/DAB, orig-
inal magnification: A ×400; B, C ×100X; D ×200
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Concerning BCCs, the histological subtypes [26] are
described in Table 1. Ten cases were of the nodular histo-
logical type (including four with an adenoid pattern) and
three of the mixed type. In three cases there was a com-
plex admixture of two types of cells: (a) cells with darkly
stained nuclei and scant cytoplasm, indistinguishable
from those observed in bona fide BCCs; (b) neoplastic
cells showing a more vesicular and atypical nuclei, with
prominent nucleoli, and more abundant eosinophilic cyto-
plasm. In all of these cases the neoplastic cells were ar-
ranged in infiltrative cords with ill-defined peripheral pal-
isades immersed in a highly desmoplastic stroma, show-
ing obvious stromal-epithelial separation artifacts; more-
over, features of squamous differentiation were observed
unevenly, but squamous pearls were not found [1]. We
preferred to classify these cases as metatypical carcino-
mas, but obviously these cases could also be classified as
BCC with incomplete squamous differentiation, inf-
iltrative borders, and intense desmoplasia [1, 19]. Ten
cases had expansive borders and six infiltrative growth
pattern. Ten cases showed low desmoplastic stromal reac-
tion; moderate and intense desmoplasia was observed in
three cases each. There was vascular/lymphatic invasion
in one case and perineurial infiltration in two others. Mi-
totic figures ranged from 2 to 56 per 10 HPF, with a mean
of 24.1 in SCCs and 23.0 in BCCs.
Maspin expression
Normal skin
In normal epidermis there was a gradual increase in cyto-
plasmic and membranous expression of maspin from the
suprabasal to spinous and granular layers (Fig. 1A). Basal
cells were uniformly negative. It should be noted that all
keratinized cutaneous structures showed maspin expres-
sion. In hair follicles maspin was consistently expressed
in the cytoplasms and on the membranes of mature cells
of germinative hair matrix layer; a cytoplasmic and mem-
Fig. 2A–D Maspin expression in squamous cell carcinomas
(SCCs). A SCC, grade II. Maspin expression in the cytoplasm of
mature squamous cells. Inset Note a mature squamous cell with
maspin nuclear expression in the center of a squamous pearl. 
B Scattered maspin expression in grade III SCC. C SCC, grade I.
Maspin strongly decorated neoplastic cells in a cytoplasmic and
membranous pattern. D SCC in situ adjacent to invasive grade III.
Note reduction in maspin expression in the suprabasal layers of
the skin. Streptavidin-biotin-peroxidase/DAB, original magnifica-
tion: A ×100; A inset, B ×400; C ×40; D ×100
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branous reactivity was also observed in the Henle’s and
Huxley’s layers as well as in the hair cuticle; focal ex-
pression of maspin was also observed in some of the cells
of the external root sheath of the hair follicles (Fig. 1B).
No immunoreactivity was observed the perifollicular con-
nective tissue sheath. Mature sebaceous cells showed in-
tense cytoplasmic reactivity for maspin as well as occa-
sional nuclear immunoreactivity (Fig. 1C). By contrast,
sweat glands showed a remarkably uneven distribution of
maspin staining. While some glands showed nuclear and
cytoplasmic immunoreactivity in all cells, others showed
only nuclear positivity in cells arranged in a basal cell or
myoepithelial-like pattern (Fig. 1D), in a similar pattern
to what has been described for maspin expression in
breast lobules and ducts. No dermal mesenchymal cell,
endothelial cell, pericyte, smooth muscle cell, neural cell,
or adipocyte showed any immunoreactivity for maspin.
Squamous cell carcinomas
The cell type specific and overall expression of maspin
is summarized in Table 2. The overall cytoplasmic ex-
pression of maspin in SCCs was largely dependent on
the proportion of keratinized cells and on the tumors’
grade (Fig. 2A). Squamous pearls showed intense cyto-
plasmic/membranous maspin immunoreactivity in the
cells around the keratinized foci (Fig. 2B). Conversely,
undifferentiated cells lacked maspin immunoreactivity or
only showed focal and weak staining. Focal nuclear ma-
spin positivity was only observed in one grade II SCC
(Fig. 2A, inset). 
In relation to grade, overall cytoplasmic maspin stain-
ing was more diffuse in well differentiated (grade I and
grade II) SCCs than poorly differentiated (grade III and
grade IV) SCCs (P=0.0099). Briefly, all grade I tumors
showed +++ positivity (Fig. 2C), four grade II tumors
were diffusely (+++) positive for maspin, one case
showed moderate and other focal immunoreactivity; in
grade III tumors, maspin was absent in one case, focally
expressed in two, and diffusely expressed in one. The
grade IV spindle cell carcinoma was completely negative
for this marker. The degree of desmoplasia showed a
trend to be inversely correlated with maspin cytoplasmic
expression (P=0.0767). Maspin did not show any other
statistical correlation with other pathological parameters.
Table 2 Maspin expression in usual cutaneous carcinomas [– neg-
ative staining, + focal positivity (<5% of neoplastic cells), ++
moderate positivity (5–50% of neoplastic cells), +++ diffuse im-
munoreactivity (>50% of neoplastic cells), BCC basal cell carci-
noma, SCC squamous cell carcinoma]
Case no. Diagnosis Histological Maspin cell type Maspin overall immunoreactivity
type/grade
Squamous Undifferentiated Nucleus Cytoplasm, 
cells basal cells membrane
1 BCC Metatypical +++ + + ++
2 BCC Metatypical ++ ++ – +++
3 BCC Metatypical ++ ++ – +++
4 BCC Nodular +++ ++ ++ +++
5 BCC Mixed – – – –
6 BCC Mixed + + – ++
7 BCC Mixed +++ +++ – +++
8 BCC Nodular – ++ – +
9 BCC Nodular – – – –
10 BCC Nodular – ++ – +++
11 BCC Micronodular – + + +
12 BCC Nodular – – – –
13 BCC Nodular – ++ – ++
14 BCC Nodular + ++ – ++
15 BCC Nodular + + – +
16 BCC Nodular – – – –
17 SCC Grade I +++ + – +++
18 SCC Grade I +++ – – +++
19 SCC Grade I +++ ++ – +++
20 SCC Grade I +++ – – +++
21 SCC Grade II +++ ++ + +++
22 SCC Grade II +++ + – +++
23 SCC Grade II +++ + – +++
24 SCC Grade II ++ – – ++
25 SCC Grade II + – – +
26 SCC Grade III + – – –
27 SCC Grade III + – – +
28 SCC Grade III +++ – – +++
29 SCC Grade III +++ – – +
30 SCC Grade IV, spindle – – – –
cell carcinoma
A marked reduction in maspin expression was ob-
served in four of seven in situ SCCs when compared to
adjacent epidermis; while in normal and reactive epider-
mis maspin was consistently expressed in the superficial
layers, in in situ SCCs it was markedly reduced and con-
fined either to the suprabasal or suprabasal and spinous
layers (Fig. 2D). However, it should be noted that the
cases evaluated here were associated with invasive SCCs
and may not reflect the distribution of maspin in preneo-
plastic lesions of the skin.
Basal cell carcinomas
All “metatypical” BCCs showed moderate to diffuse
overall cytoplasmic expression of maspin. Three nodular
BCCs lacked maspin immunoreactivity; two were focal-
ly (+) positive; two were moderately immunoreactive
(++); and three showed immunoreactivity in more than
50% of neoplastic cells (+++). Mixed BCCs showed
highly variable overall maspin expression; one case was
negative, one focally positive, and one diffusely immu-
noreactive. Notably, nodular and mixed BCCs showed an
interesting pattern of maspin immunoreactivity, with ma-
spin positive cells confined to the central region of the
neoplastic clusters (Fig. 3A). However, in metatypical
BCCs maspin was expressed either in the central as in
the periphery of cells cords and clusters (Fig. 3B). There
was no statistical correlation between overall maspin ex-
pression and other pathological parameters. Concerning
nuclear expression of maspin, only two nodular BCCs
and one metatypical BCC revealed this pattern of reac-
tivity.
Discussion
Maspin is one of the serpins that have received great at-
tention by basic researchers and pathologists during the
past few years [9, 5, 6, 11, 12, 14, 15, 16, 17, 18, 20, 21,
22, 23, 24, 25, 27, 28, 31, 35, 36, 37]. Since its charac-
terization several biological properties have been attrib-
uted to maspin, including tumor suppressor and antian-
giogenic activities [9, 14, 15, 22, 27, 28, 36, 37]. It is
also considered as a suppressor of invasion, motility,
proliferation, and metastatic potential of neoplastic cells
[9, 5, 6, 11, 12, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25,
27, 28, 31, 35, 36, 37]. Moreover, there are controversial
data on the role of maspin as a downstream factor of p53
pathway [9, 14, 18, 33, 37, 38].
Much has been reported regarding maspin function
and its subcellular localization [9, 17, 20, 21, 23, 27].
Some studies describe maspin as a soluble cytoplasmic
protein that associates with secretory vesicles and is also
present on the cell surface [21, 27]. We [23, 24, 25] and
others [12, 17, 20] have demonstrated that maspin is also
expressed in the nuclei of myoepihelial cells, myoepithe-
lial cell tumors, and in some breast carcinomas [12, 20,
23, 24, 25]. However, in the present study we report for
the first time, maspin expression in the nuclei of scat-
tered neoplastic cells in SCCs and BCCs. Moreover,
sweat gland basal cells were consistently decorated by
maspin, both in nuclear and cytoplasmic compartments.
These observations are in accordance with the findings
of Takeda et al. [30], who analyzed the expression SCC
antigens 1 and 2 in psoriatic skin samples using conven-
tional immunohistochemistry and immunoelectron mi-
croscopy and found that these serpins are abundantly ex-
pressed in the nuclei of the granular layer cells and of
keratinocytes of elongated rete ridges [37]. Moreover,
ovalbumin, another serpin, may also present a nucleocy-
toplasmic distribution [4].
Similar findings regarding myeloid and erythroid nu-
clear termination stage-specific protein nuclear expres-
sion have been published by Irving et al. [10]. In the nu-
clear compartment this serpin plays a very interesting
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Fig. 3A–D Maspin expression in basal cell carcinomas. A BCC
with invasive borders and intense desmoplasia: maspin is ex-
pressed at the periphery and center of infiltrative cords. B BCC,
nodular type: maspin is expressed in the center of the nodules.
Note that peripheral palisading basal cells lack maspin expression.
Inset Maspin expression in the nuclei of scattered neoplastic basal
cells. Streptavidin-biotin-peroxidase/DAB, original magnification:
A ×200; B ×100; B inset ×400X
role in chromatin structure and in cell proliferation [10].
Based on these findings [4, 10, 12, 17, 20, 23, 24, 25,
37] one might hypothesize that nuclear expression of
maspin is related to specific histogenetic phenotypes
and/or pathways of differentiation, and that some of the
tumor suppressing properties previously reported for ma-
spin are related to its putative functions on chromatin re-
modeling and cell proliferation. Obviously further stud-
ies are needed to clarify the intriguing roles of maspin in
the nuclei of normal and neoplastic cells.
Recently, Xia et al. [33] and Yasumatsu et al. [34]
demonstrated that maspin is expressed in a subset of oral
SCCs with favorable prognosis; in accordance with the
findings of Yasumatsu et al. [34], in the present study we
also observed that maspin is preferentially expressed in
well-differentiated SCCs. Moreover, maspin was consis-
tently expressed in almost all squamous pearls. As previ-
ously reported [33, 34], maspin expression was not sta-
tistically correlated with other pathological features of
SCCs, including cell proliferation, growth pattern, and
degree of desmoplasia in the stroma.
This is the first study to evaluate maspin expression
in BCC of the skin. No statistical association between
maspin and classical pathological features was observed.
Interestingly, we observed a remarkable difference in the
distribution of maspin in metatypical carcinomas and
nodular BCCs. While the first showed diffuse cytoplas-
mic immunoreactivity, even in the borders of cell cords
and clusters, the later revealed a distinctive distribution
in the center of cell nodules. Again, this militates against
a role of maspin on the blockage of invasion by neoplas-
tic cells. Remarkably, we observed that maspin was con-
sistently expressed in cells showing squamous differenti-
ation in all BCCs evaluated here. Based on these obser-
vations and on the higher expression of maspin in well
differentiated SCCs, we again hypothesize that maspin
plays a role in terminal squamous differentiation. Again,
experimental studies should be carried out in order to de-
finitively clarify this issue.
In contrast to other tumor suppressor genes, mutations
and deletions of the maspin gene are exceedingly rare
and do not seem to result in the loss of maspin expres-
sion [5, 6, 9]. Recently Domann et al. [5] and Futscher et
al. [6] shed light on the regulation of the tissue specific
distribution of maspin as well as in the putative mecha-
nisms of downregulation of maspin expression in human
neoplasms [5, 6]. These studies demonstrated that the
methylation status of the CpG island of the maspin gene
promoter is inversely correlated with maspin expression:
while blood lymphocytes, skin fibroblasts, bone marrow
cells, heart muscle and kidney epithelial cells do not ex-
press maspin and have dense methylation of maspin gene
promoter; airway epithelium, breast and prostate “epithe-
lial” cell lines as well as skin and oral keratinocytes lack
methylation of maspin gene promoter and consistently
express maspin [5, 6]. Most importantly, Futscher et al.
[6] also showed that maspin expression-immortalized fi-
broblasts can express maspin after treatment with a DNA
methyltransferase inhibitor 5-aza-2′-deoxycytidine [6].
Further regulation of tissue specificity of maspin ex-
pression may be related to the presence of an hormonal
responsive element (HRE) in the maspin gene promoter,
which downregulates the transcription of this gene [35,
39]. It has been shown that activated androgen receptors
(ARs) can bind to the HRE and block the transcription of
maspin in prostate cancer cell lines [35]. ARs are ubiqui-
tously distributed in the human body, and it would be
tempting to speculate that ARs play a role in the regula-
tion of maspin expression in cutaneous structures [2, 3,
8, 29]. In the skin ARs are consistently observed in sebo-
blasts and in a variable proportion of sebocytes [3, 8,
29]. In other cutaneous structures, such as dermal papilla
of hair follicles, hair follicle epithelial cells, eccrine and
apocrine sweat glands, and keratinocytes, ARs show
highly variable expression [3, 8, 29]. The discrepancies
observed in numerous studies may be related to the dif-
ferences in the tissue samples (frozen vs. formalin-
fixed), immunohistochemical methods, and antibodies
used to assess their distribution [2, 3, 8, 29]. Notably, in
contrast to what have been described in prostate carcino-
ma cell lines, in which maspin expression is negatively
regulated by ARs [35], mature sebocytes concurrently
express maspin and ARs. Moreover, up to 60% of BCCs
expresses ARs [3] and also express maspin. Thus the
role of ARs in the regulation of maspin expression in
normal skin and cutaneous neoplasms remains unsettled.
In conclusion, we described maspin expression in
normal skin, cutaneous appendages, SCCs, and BCCs.
We demonstrated that maspin is consistently expressed
in the cytoplasm of keratinocytes of suprabasal, granular,
and spinous layers, in terminally differentiated seba-
ceous cells, and in the inner root sheath cells of hair fol-
licles. Interestingly, a nuclear distribution of maspin was
observed in the nuclei of basal cells of sweat glands and
occasional differentiated sebaceous cells as well as in
two BCCs and one SCC. In SCCs maspin was strongly
expressed in cells showing features of terminal squa-
mous differentiation; in contrast, nodular BCCs show a
peculiar distribution of maspin, while metatypical carci-
noma cells were strongly decorated by maspin.
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